Skip to content

EBITDA at other companies

Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.1M+35.1%
Savara logo
SavaraSVRA
-$38.97M-37.2%
LQD
Liquidia CorporationLQDA
$62M+277%
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
$11.92M+14.0%
Intuitive Surgical logo
Intuitive SurgicalISRG
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Calculated from Pulmonx Corporation’s reported figures.

$13.0Mebit+
$220.0KDepreciation Depletion & Amortization
=-$12.74M

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's EBITDA?
Pulmonx Corporation (LUNG) reported EBITDA of -$12.74M in Q1 2026.
How has Pulmonx Corporation's EBITDA changed year-over-year?
Pulmonx Corporation's EBITDA increased by 10.8% year-over-year, from -$14.29M to -$12.74M.
What is the long-term trend for Pulmonx Corporation's EBITDA?
Over 4 years (2021 to 2025), Pulmonx Corporation's EBITDA has grown at a 3.2% compound annual growth rate (CAGR), from -$46.44M to -$52.61M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.